CervoMed Developed New Oral Tablet Formulation

The company introduced a stable 50 mg tablet designed to improve the pharmacokinetic profile of neflamapimod.

Updated on Sept. 28, 2026 in Veterinary Medicine

Isometric editorial illustration of a single pharmaceutical tablet placed on a clean geometric surface, representing a medical formulation breakthrough. — CervoMed has developed a stable 50 mg neflamapimod tablet, allowing the company to advance to a 100 mg twice-daily dosage regimen following FDA regulatory clearance. AI Illustration. Upload story photo >

Live Poll

Can pharmaceutical companies be trusted to prioritize patient safety when modifying drug formulations and dosing limits?

CervoMed has developed a new 50 mg neflamapimod tablet that demonstrates superior drug stability and a improved pharmacokinetic profile. The FDA subsequently removed the plasma drug exposure limit for the treatment following a 39-week dog toxicology study.

Why it matters

This new formulation resolves manufacturing variability observed in previous clinical trials, such as the Phase 2b RewinD-LB study. By overcoming these stability issues, the company has cleared a regulatory hurdle that allows for higher dosage regimens in future trials.

The 50 mg tablet shows 20% lower peak plasma concentration and 20% higher plasma concentration 12 hours post dose than earlier iterations. The new NOAEL is 30-fold above the active exposure range.

The players

CervoMed

CervoMed is a clinical-stage company headquartered in Boston that focuses on developing treatments for neurodegenerative diseases.

FDA

The Food and Drug Administration is the federal agency responsible for regulating and approving medical treatments and research protocols in the United States.

The details

The Boston-based company implemented a controlled manufacturing process to produce the stable crystalline tablets. The regulatory shift allows CervoMed to advance a 100 mg twice-daily regimen, which is projected to boost trough plasma drug concentrations by 33%.

A 39-week dog toxicology study was completed in the first half of 2026.
Clinical data for the 80 mg twice-daily regimen was presented in July 2026.
CervoMed announced these pharmacokinetic and regulatory advances on September 28, 2026.
Interim biomarker data from the nfvPPA Phase 2a trial is expected in early Q4 2026.
The EXPERTS-ALS trial is slated for first patient dosing in Q4 2026.

Asthma
Sept. 28
GRI Bio Will Present IPF Research Findings in Boston
Biotech
Sept. 28
Samsung Biologics Presented New Tech in Boston
Cancer
Sept. 23
ITM and Lumara Bio Will Present Cancer Study Data

Roadmap

This development marks a significant transition from variable-output capsules to a standardized crystalline tablet architecture. By stabilizing the delivery mechanism, the company aligns its production capabilities with the rigorous pharmacokinetic requirements needed for advanced neurodegenerative research.

The refinement of this manufacturing process supports the company's broader clinical pipeline and future trial feasibility. Local investors and stakeholders should note that the regulatory approval for higher dosage regimens positions the firm for critical trial milestones later this year.

The takeaway

The move to a stable crystalline 50 mg tablet enables more reliable dosing and provides a path for testing higher medication concentrations in human patients. This regulatory progress underscores how iterative improvements in manufacturing can remove significant barriers to clinical development.

What happens next

CervoMed expects to release interim biomarker data from its nfvPPA Phase 2a clinical trial in early Q4 2026. Additionally, the company is scheduled to begin dosing the first patients in the EXPERTS-ALS trial during Q4 2026.